OmegaQuant Analytics, the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level.
Photo © iStockphoto.com/Rinelle
OmegaQuant Analytics (Siox Falls, SD), the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level. This is an important measure for pregnant women because there is evidence that deficiency in omega-3 long chain polyunsaturated fatty acids can increase the risk of preterm birth.
A meta-analysis1 conducted by Cochrane of 70 randomized control trials, involving 19,927 women, found that preterm birth (<37 weeks of gestation) and very preterm birth (<34 weeks of gestation) was reduced by 11% and 42% respectively when women took omega-3 supplements, and determined that it is an effective strategy for reducing the risk of preterm births. Another recent study2 found that the risk of early preterm birth (<34 weeks of gestation) was 10 times higher in women in the lowest quintile, with an EPA and DHA omega-3 concentration of less than 1.6% of total plasma fatty acids.
Using this data, and converting the EPA and DHA plasma levels to red blood cell DHA levels, OmegaQuant determined that pregnant women should strive to have DHA levels of at least 5% (meaning that 5% of her red blood cell fatty acids are DHA). “In a study3 we published in December, we estimated that 70% of women of childbearing age in the US are below the 5% DHA cutoff. There are no known risks to having a DHA level that is too high in pregnancy, except for the potential of carrying a baby past 40 weeks. Still, the longer a baby can stay in the womb, the lower the chances are for complications,” said Kristina Harris Jackson, PhD, RD, a research associate at OmegaQuant Analytics, in a press release. “It’s hard to think of a more important biomarker than prenatal DHA levels that can be safely and easily modified and has such potentially consequential outcomes.”
1. Middleton P. et al. “Omega-3 fatty acid addition during pregnancy.” Cochrane Database of Systematic Reviews, vol 11 (November 2018)
2. Olsen S.F. et al. “Plasma concentrations of long chain omega-3 fatty acids in early and mid-pregnancy and risk of early preterm birth.” EBioMedicine, vol 35 (September 2018): 325-333
3. Jackson K.H et al. “A prenatal DHA test to help identify women at increased risk for early preterm birth: a proposal.” Nutrients, vol 10, no. 12 (December 2018)
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.